Biomarker Core

生物标志物核心

• 批准号: 10475321
• 负责人: ALLEN W SONG
• 金额: $ 48.79万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10475321
• 关键词: Affect; Algorithms; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Alzheimer’s disease biomarker; Amyloid; Area; Biological Markers; Blood; Brain; Brain imaging; Caliber; Cells; Clinical; Collaborations; Communities; Cortical Column; Data; Data Analyses; Databases; Dementia; Detection; Development; Disease; Disease Progression; Early Diagnosis; Enrollment; Environmental Risk Factor; Faculty; Family; Funding; Genetic Risk; Genomics; Goals; Human; Image; Image Analysis; Imaging Device; Individual; Investigation; Knowledge; Lead; Magnetic Resonance Imaging; Measures; Methodology; Modality; Monitor; Nerve Degeneration; Neurodegenerative Disorders; Organ; Participant; Patients; Persons; Positron-Emission Tomography; Prevention; Proteins; Proteomics; Provider; Research; Research Personnel; Research Project Grants; Resolution; Resources; Sensory; Signal Transduction; Standardization; Symptoms; Synapses; Time; Tracer; Training; Work; adjudicate; age related; biomarker development; cohort; data acquisition; data management; density; disease diagnosis; early detection biomarkers; education research; experience; high risk population; human old age (65+); human subject; imaging biomarker; improved; innovation; magnetic resonance imaging biomarker; metabolomics; next generation; novel; novel marker; outreach; pre-clinical; recruit; resilience; retinal imaging; standardize measure; statistics; tau Proteins; wearable device

ABSTRACT – BIOMARKER CORE The objective of the Biomarker Core is to acquire and analyze biofluid and imaging biomarkers, characterize their relevance to Alzheimer’s disease (AD), and determine the underlying age-related factors that drive the development, progression, or experience of the disease. To achieve these goals, we bring together experts across diverse backgrounds in genomics, proteomics, metabolomics, and imaging to provide institutional resources to serve ADRC investigators, help initiate new collaborations, and train the next generation of AD and Alzheimer’s disease-related dementia (AD+ADRD) biomarkers researchers. Specifically, we propose four aims: 1) Acquire conventional and novel biomarkers in biofluid (CSF, blood), brain images (PET, MRI), and sensory organ data (retinal imaging) in adjudicated participant groups. Working closely with the Clinical Core, we will acquire CSF, blood, PET and MRI biomarkers in our clinical cohort to submit to the National Alzheimer’s Coordinating Center (NACC). At the same time, we will collaborate closely with independently funded research projects to acquire novel and early biomarkers in high-risk populations during the prodromal or early symptomatic stages of AD pathology. 2) Analyze biomarkers to obtain standardized measures and support relevant funded research projects within the ADRC community. We will perform standardized analyses in biofluid and imaging data to extract conventional biomarkers, and collaborate with existing funded projects to develop specialized analytics to identify novel biomarkers that can lead to earlier detection and prevention. 3) Provide resources to ADRC researchers integrating standardized multi-dimensional biomarkers data across all participants to characterize the underlying age-related drivers for AD. Working closely with the Data Management and Statistics Core, we will create and curate a multi-dimensional database, integrating all acquired biomarkers and clinical measures. This database will be used to assist and train the next generation of AD researchers in their investigations of underlying age-related drivers of AD, through collaborations with the Research Education Component. 4) Disseminate our expertise and knowledge to support the AD community at large. Working with the Outreach, Recruitment, and Engagement Core, we will disseminate our expertise and knowledge on established and emerging biomarkers to the local AD stakeholder community, other ADRC centers, and AD+ADRD researchers and providers across the nation. Through these four aims, we hope to help achieve our overall objective to catalyze and support high- caliber research and innovations to reduce the burden of AD and its impact on patients and families.

摘要 - 生物标志物核心 生物标志物核心的目的是获取和ZE生物流体和成像生物标志物 它们与阿尔茨海默氏病（AD）相关 发展，进步或实现这些目标的经验，我们将专家汇集在一起 跨基因组学，蛋白质组学，代谢组学和成像的各种背景，以提供机构 为ADRC调查人员提供服务的资源，帮助启动新的合作，并培训下一个 我们建议，我们建议，阿尔茨海默氏病（AD+ADRD）的生物标志物研究人员 四个目的：1）在生物流体（CSF，血液），脑图像（PET，MRI）中获取常规和新型生物标志物， 和裁决的参与者组中的感觉器官数据（视网膜成像）。 核心，我们将在我们的临床队列中获得CSF，血液，PET和MRI生物标志物 阿尔茨海默氏症协调中心（NACC）。 在生产期间，资助的研究项目以获取高风险人群中的新颖和早期生物标志物 或AD病理的早期症状阶段。 支持ADRC社区中相关资助的研究项目。 在生物流体和成像数据中进行分析以提取ContentCtct ConcuttionTionTimarkers，并与现有 资助的项目以开发专业分析，以识别可以导致早期检测的新型生物标志物 和预防3）为ADRC研究人员提供资源 跨高温剂的生物标志物数据表征与年龄相关的驱动器分叉 与数据管理和统计核心紧密相关，我们将创建和策划多维 数据库，整合所有获得的生物标志物和临床措施。 培训下一代广告研究人员对与年龄相关的AD驱动因素的调查， 通过与研究教育部分的合作。 知识支持广告社区。 核心，我们将把我们的专业知识和知识传播到当地的新兴生物标志物 广告利益相关者社区，其他ADRC中心以及您的AD+ADRD研究人员和提供商 国家。 Caliver的研究和创新，以减轻广告的负担，其对患者和家庭的影响。